• 1. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 2. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 3. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 4. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 5. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Phenylpyridines

5-(3,5-Difluorophenyl)nicotinamide: A Comprehensive Overview

5-(3,5-Difluorophenyl)nicotinamide (CAS No. 1346691-76-6) is a synthetic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, characterized by its unique chemical structure and potential biological activities, has been the subject of numerous studies aimed at elucidating its properties and applications.

The chemical structure of 5-(3,5-Difluorophenyl)nicotinamide consists of a nicotinamide moiety attached to a 3,5-difluorophenyl group. This combination imparts specific physicochemical properties that make it an interesting candidate for various biological investigations. The presence of the fluorine atoms in the phenyl ring enhances the compound's lipophilicity and metabolic stability, which are crucial factors in drug design and development.

Recent research has focused on the potential therapeutic applications of 5-(3,5-Difluorophenyl)nicotinamide. One notable area of interest is its activity as a modulator of nicotinic acetylcholine receptors (nAChRs). These receptors play a pivotal role in various physiological processes, including neurotransmission, cognition, and pain modulation. Studies have shown that 5-(3,5-Difluorophenyl)nicotinamide exhibits selective binding to specific subtypes of nAChRs, which could make it a valuable tool in the development of novel treatments for neurological disorders such as Alzheimer's disease and Parkinson's disease.

In addition to its potential as a receptor modulator, 5-(3,5-Difluorophenyl)nicotinamide has also been investigated for its anti-inflammatory properties. Inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease, are characterized by chronic inflammation that can lead to tissue damage and functional impairment. Preclinical studies have demonstrated that 5-(3,5-Difluorophenyl)nicotinamide can reduce inflammatory markers and alleviate symptoms in animal models of these diseases. This suggests that it may have therapeutic potential in managing inflammatory conditions.

The pharmacokinetic profile of 5-(3,5-Difluorophenyl)nicotinamide has also been studied extensively. Research indicates that it exhibits favorable absorption, distribution, metabolism, and excretion (ADME) properties. Its high oral bioavailability and low toxicity profile make it an attractive candidate for further clinical development. Additionally, the compound's ability to cross the blood-brain barrier (BBB) is a significant advantage for targeting central nervous system (CNS) disorders.

Clinical trials are currently underway to evaluate the safety and efficacy of 5-(3,5-Difluorophenyl)nicotinamide in human subjects. Early-phase trials have shown promising results, with the compound demonstrating good tolerability and preliminary evidence of therapeutic benefit. However, more extensive studies are needed to fully understand its potential and to optimize dosing regimens for different indications.

Beyond its therapeutic applications, 5-(3,5-Difluorophenyl)nicotinamide has also found use as a research tool in academic and industrial laboratories. Its unique chemical structure makes it an ideal probe for studying the structure-activity relationships (SARs) of nicotinic receptor ligands. By modifying the core structure or substituents of the compound, researchers can gain insights into the molecular mechanisms underlying receptor activation and modulation.

In conclusion, 5-(3,5-Difluorophenyl)nicotinamide (CAS No. 1346691-76-6) is a multifaceted compound with promising applications in both therapeutic and research settings. Its unique chemical properties and biological activities make it a valuable asset in the ongoing efforts to develop new treatments for neurological disorders and inflammatory diseases. As research continues to advance our understanding of this compound, it is likely to play an increasingly important role in the fields of medicinal chemistry and pharmaceutical science.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)